| 05/15/08 |
Pro-Pharmaceuticals Reports First Quarter Results. |
| 05/01/08 |
PRO-PHARMACEUTICALS UPDATES NDA FILING FOR DAVANAT®.
Follows FDA Guidance to Provide Chemistry, Manufacturing & Controls Data. |
| 04/14/08 |
Pro-Pharmaceuticals Announces Change in Auditors. |
| 04/07/08 |
Pro-Pharmaceuticals Announces Commercialization Plans For DAVANAT® With YIACO Medical.
YIACO Medical Represents 80 Health Care Companies and Serves 18 Countries with a Population of 400 Million. |
| 03/28/08 |
Pro-Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results.
The Company Plans to File a New Drug Application with the FDA for DAVANAT®. |
| 03/24/08 |
Pro-Pharmaceuticals Announces DAVANAT® Regimen Approved to Treat Breast Cancer Patient. |
| 03/03/08 |
Pro-Pharmaceuticals
DAVANAT® Extends Median Survival 6.7 Months for
End-Stage Colorectal Cancer Patients After All Other
Treatments Failed. |
| 02/28/08 |
Pro-Pharmaceuticals
Closes Financing. |
| 02/15/08 |
Pro-Pharmaceuticals
Enters into Definitive Agreements for $3.775 Million
Financing. |
| 02/11/08 |
New
Data Shows DAVANAT® Extends Survival of End-Stage
Colorectal Cancer Patients More Than 6 Months.
Pro-Pharmaceuticals Tracks Patients After Phase ll
Trial: Two Patients Survived More Than 2 Years.
|
| 02/08/08 |
Pro
Pharmaceuticals Teams With UMass-Lowell On Target
Drug Therapy.
source:
Nanowerk
News
The
Daily Collegian (Matt Sheehan) |
| 02/06/08 |
Pro-Pharmaceuticals
Notes That Shelf Registration is Effective. |
| 01/31/08 |
Pro-Pharmaceuticals
to Present Corporate Update at Russ Trading Investor
Meeting in Tempe, Arizona, and Red Chip Small Cap
Conference in Scottsdale. |
| 01/29/08 |
Pro-Pharmaceuticals
Phase ll Trial Shows DAVANAT® Improves Median
Progression Free Survival with Fewer Side Effects
as Compared to Recent Similar Studies. |
| 01/29/08 |
Pro-Pharmaceuticals
Files $10 Million Shelf Registration. |
| 12/28/07 |
Pro-Pharmaceuticals
Plans to Present a Corporate Update at the Red Chip
Small Cap Investor Conference. |
| 12/19/07 |
Pro-Pharmaceuticals
Selects SAFC®, a Division of SIGMA- ALDRICH™,
to Submit a Drug Master File.
An Important Step in the NDA Approval Process for
DAVANAT®. |
| 12/12/07 |
Pro-Pharmaceuticals
Enters Research Collaboration with University of Massachusetts
Lowell. |
| 12/06/07 |
Pro-Pharmaceuticals
& Brigham and Women's Hospital Announce New Kidney
Fibrosis Research Collaboration. |
| 11/14/07 |
Pro-Pharmaceuticals
Reports Third Quarter Results. |
| 10/30/07 |
Pro-Pharmaceuticals
to Present:
“Advancing Drugs Through Glycoscience®”
at Rodman & Renshaw’s Healthcare Conference.
|
| 10/17/07 |
Pro-Pharmaceuticals
Novel Carbohydrate Compounds Reverse Liver Fibrosis
in Pre-clinical Studies. |
| 10/11/07 |
Pro-Pharmaceuticals
Reports 43% Response Rate in Colorectal Trial; No
Hematological or Gastrointestinal Serious Adverse
Events Reported. |
| 10/02/07 |
Pro-Pharmaceuticals
Names Anthony Squeglia Chief Financial Officer; Steven
Schubert Vice President Finance.
|
| 09/24/07 |
Pro-Pharmaceuticals
Names Theodore Zucconi, Ph.D., President; Nominated
to the Board of Directors.
|
| 09/14/07 |
Amex
Accepts Pro-Pharmaceuticals Plan of Compliance. |
| 08/20/07 |
Pro-Pharmaceuticals’
Sponsored Symposium on Galectins Begins Today as Part
of the American Chemical Society’s 234th Annual
Meeting & Exposition.
Proposed Mechanism of Action for the Company’s
Lead Compound DAVANAT®: Targets Galectin Receptors
on Cancer Cells. |
| 08/16/07 |
Pro-Pharmaceuticals
Announces “Compassionate Use” IND for
DANANAT® to Treat Biliary Cancer Patient. |
| 08/10/07 |
Pro-Pharmaceuticals
Reports Second Quarter Results. |
| 08/03/07 |
Pro-Pharmaceuticals
Retains Camargo Pharmaceutical to Provide Strategic
Regulatory Support for 505(b)(2) Submissions.
|
| 07/27/07 |
Pro-Pharmaceuticals
Issues Corporate Update.
|
| 07/25/07 |
Pro-Pharmaceuticals
Announces Boston Medical Center Dosing Patients with
DAVANAT® in Advanced Biliary Cancer Trial.
|
| 07/24/07 |
Pro-Pharmaceuticals
Submits Plan of Compliance to Amex.
|
| 07/23/07 |
Pro-Pharmaceuticals
Enters Research Agreement with Global Bio-pharmaceutical
Company.
|
| 07/09/07 |
Pro-Pharmaceuticals
Updates Progress
Of Clinical Trials & DAVANAT® 505 (B)(2) Filings.
Phase ll Colorectal Cancer Patients Stabilized Up
to 7 Months; Phase ll Biliary Cancer Patients Stabilized
Up to 5 Months.
Patients Experience No Increase in Drug-Related Toxicity
& Reduced Side Effects with Increased Exposure
to 5-FU & AVASTIN®.
Plans to Submit Manufacturing Data for DAVANAT®
505 (b)(2) Filings to the FDA this Year; No Additional
Toxicity or Clinical Trial Data Needed. |
| 07/02/07 |
Pro-Pharmaceuticals
Terminates Financing Agreement.
The Company is Evaluating other Financing Alternatives.
|
| 06/26/07 |
Pro-Pharmaceuticals
Reports Receipt of Notice from Amex.
|
| 06/19/07 |
Pro-Pharmaceuticals
Enters into Definitive Agreements for a $2.7 Million
Financing.
|
| 06/14/07 |
Pro-Pharmaceuticals
to Sponsor American Chemical Society’s Special
Symposium on Galectins.
Proposed Mechanism of Action for the Company’s
Lead Compound DAVANAT®: Binds to Galectin Receptors
on Cancer Cells.
|
| 06/11/07 |
Pro-Pharmaceuticals
Submits Data to Begin a
505 (b)(2) Filing with the FDA for a New Formulation
of Irinotecan to be Co-administered with DAVANAT®
as a Functional Excipien.
Irinotecan is a Leading Chemotherapy Drug in Colorectal
Cancer Treatment. |
| 05/17/07 |
Pro-Pharmaceuticals
to Present Abstract at the International Society of
Oncodevelopmental Biology and Medicine Conference. |
| 05/15/07 |
Pro-Pharmaceuticals
Reports First Quarter Results. |
| 05/14/07 |
Pro-Pharmaceuticals
Issues Clinical Trial Update. |
| 05/08/07 |
Pro-Pharmaceuticals
to Present and Webcast
at Rodman & Renshaw’s Global Healthcare
Conference.
|
| 04/30/07 |
Pro-Pharmaceuticals
and Digna Biotech Sign Agreement to Apply DAVANAT®
with Novel Drugs to treat Hepatitis C. |
| 04/17/07 |
Pro-Pharmaceuticals
Issues Corporate Update. |
| 04/16/07 |
S.
Colin Neill Nominated to Pro-Pharmaceuticals Board
of Directors. |
| 04/12/07 |
Pro-Pharmaceuticals
Plans to Submit a New Drug Application for DAVANAT®,
as a Functional Excipient, with 5-FU to Treat Cancer. |
| 04/11/07 |
Pro-Pharmaceuticals
Receives Letter from the FDA for New Drug Application
for DAVANAT®/ 5-FU.
FDA
Considers DAVANAT® a “Novel” Excipient.
|
| 04/04/07 |
Pro-Pharmaceuticals
Announces Tampa General Hospital Dosing Patients with
DAVANAT®/5-FU in Phase II, First Line, Advanced
Biliary Cancer Clinical Trial. |
| 04/02/07 |
Pro-Pharmaceuticals
Reports Fourth Quarter and Full Year 2006 Financial
Results.
Annual Shareholders Meeting Scheduled for May 24th. |
| 03/21/07 |
Pro-Pharmaceuticals
Restructures Convertible Debentures. |
| 02/28/07 |
Pro-Pharmaceuticals
Submits Orphan Drug Status Application to European
Medicines Agency.
Co-administration of DAVANAT® with 5-FU to Treat
Cholangiocarcinoma. |
| 02/27/07 |
Pro-Pharmaceuticals
Announces Third Site Dosing Patients with DAVANAT®
in Phase ll, First Line, Colorectal Cancer Clinical
Trial. |
| 02/23/07 |
Pro-Pharmaceuticals
Meeting Scheduled with the FDA.
April 11th Meeting to Discuss NDA Submission for Co-administration
of DAVANAT® with 5-FU to Treat Cancer Patients.
|
| 02/20/07 |
Pro-Pharmaceuticals
Collaborates with Chemwerth to Scale Up Production
of DAVANAT® for Initial Marketing Needs.
Chemwerth Scales Up DAVANAT® to 100 Kilos per
Batch. |
| 02/16/07 |
Pro-Pharmaceuticals
to Account for Warrants as Liabilities from 2003 and
2004 Equity Finance Transactions.
Liability Treatment Does Not Change Operating Expenses
or Cash Position. |
| 02/12/07 |
Pro-Pharmaceuticals
Requests Meeting with the FDA to Discuss New Drug
Application for
Co-administration of DAVANAT® with 5-FU to Treat
Cancer Patients.
5-FU is one of the most widely used chemotherapy drugs
in the world. |
| 02/07/07 |
Pro-Pharmaceuticals’
Begins Process of New Drug Application Submission
with the FDA for Co-administration of DAVANAT®
with 5-FU
in Cancer Patients. |
| 01/23/07 |
Pro-Pharmaceuticals
Announces Dosing of Patients with DAVANAT® in
Phase II, First Line, Advanced Biliary Cancer Clinical
Trial. |
| 12/22/06 |
Pro-Pharmaceuticals
Provides Corporate Update of 2006 Achievements and
2007 Objectives. |
| 12/20/06 |
Pro-Pharmaceuticals
Appoints Dr. James Gourzis to its Board of Directors. |
| 12/19/06 |
Pro-Pharmaceuticals
Signs Agreement with CESAR to Expand Recruitment of
Patients for the Phase ll Biliary Cancer Trial. |
| 11/27/06 |
Pro-Pharmaceuticals
Announces Dosing of Patients with DAVANAT® in
Phase II, First Line, Colorectal Cancer Clinical Trial. |
| 11/21/06 |
Rodman
& Renshaw, LLC Initiates Research Coverage on
Pro-Pharmaceuticals. |
| 11/13/06 |
Pro-Pharmaceuticals
Reports Third Quarter 2006 Results. |
| 11/01/06 |
Pro-Pharmaceuticals
to Present a Corporate Update at Rodman & Renshaw
Healthcare Conference; ''Advancing Drugs Through Glycoscience''
Presentation to be Webcast.
|
| 10/30/06 |
Pro-Pharmaceuticals
to Present a Corporate Update at MASS Opps: a Biotechnology
Investment Conference. |
| 10/17/06 |
Pro-Pharmaceuticals
to Present at BIO Investor Forum. |
| 09/28/06 |
Pro-Pharmaceuticals
Announces Cash Payment of Debentures & Clinical
Trial Progress. |
| 08/30/06 |
Pro-Pharmaceuticals
Updates Clinical Trials Progress. |
| 08/14/06 |
Pro-Pharmaceuticals
Reports Second Quarter 2006 Results. |
| 07/25/06 |
Pro-Pharmaceuticals
Files Phase II Clinical Trial Protocol for First Line
Treatment of Colorectal Cancer Patients.
Regimen Includes DAVANAT® with Avastin(R), 5-FU
& Leucovorin. |
| 06/05/06 |
Pro-Pharmaceuticals'
Abstract Published in ASCO Annual Meeting Proceedings.
Company Provides Clinical Trial Update. |
| 05/31/06 |
Pro-Pharmaceuticals'
Executives Contribute to New Book ''Carbohydrate Drug
Design'' Published by American Chemical Society. |
| 05/24/06 |
Pro-Pharmaceuticals
& Mount Sinai School of Medicine Announce New
Liver Fibrosis Research Collaboration. |
| 05/22/06 |
Pro-Pharmaceuticals
Reports First Quarter 2006 Financial Results.
Annual Shareholders Meeting Scheduled for May 25th. |
| 05/09/06 |
Pro-Pharmaceuticals
to Present Corporate Update at Rodman & Renshaw
Global Healthcare Conference.
''Advancing Drugs Through Nanotechnology Glycoscience''
Presentation to be Available via Webcast. |
| 05/08/06 |
Pro-Pharmaceuticals
Retains Dr. James T. Gourzis to Provide Clinical Management
& Strategic Development of Its Europe-Based Phase
III Colorectal Cancer Trial. |
| 04/10/06 |
Dr.
Henry Esber Nominated to Pro-Pharmaceuticals Board
Of Directors. |
| 04/07/06 |
Pro-Pharmaceuticals'
CEO to Present Corporate Update at BIO Annual Convention. |
| 04/05/06 |
Pro-Pharmaceuticals
Reports Preliminary Data Shows an Objective Partial
Tumor Response in Phase II Colorectal Cancer Trial
Evaluating DAVANAT® with 5-FU. |
| 03/30/06 |
Pro-Pharmaceuticals
Completes Patient Enrollment in Stage 1 of Phase II
Colorectal Cancer Trial Evaluating DAVANAT® with
5-FU. |
| 03/23/06 |
Pro-Pharmaceuticals
to Present Corporate Update at Russ Trading Hosted
Event in Scottsdale, Arizona. |
| 03/22/06 |
Pro-Pharmaceuticals
Featured on ''American Scene'' Financial Talk Radio
Show. |
| 03/17/06 |
Pro-Pharmaceuticals'
Abstract Accepted for Publication in ASCO Annual Meeting
Proceedings. |
| 03/16/06 |
Pro-Pharmaceuticals
Continues to Strengthen
Intellectual Property Portfolio.
Fifth U.S. Patent Covers Co-administration of a Carbohydrate
with a Chemotherapy Agent to Treat Cancer. |
| 03/14/06 |
Pro-Pharmaceuticals'
CEO Featured on Wall Street Reporter. |
| 03/10/06 |
Pro-Pharmaceuticals
Reports Unaudited Fourth Quarter and Full Year 2005
Financial Results.
|
| 03/02/06 |
Pro-Pharmaceuticals
to Present Abstract & Poster at Mass Biotechnology
Council Discovery Day Symposium.
|
| 02/24/06 |
Pro-Pharmaceuticals
Presents Phase II/III Clinical Trials at the Central
European Society for Anti-Cancer Drug Research Conference. |
| 02/15/06 |
Pro-Pharmaceuticals
Announces $10 Million Financing. |
| 02/02/06 |
Pro-Pharmaceuticals
Receives 'Compassionate Use' IND for Use of DAVANAT®/5-FU
to Treat Another Patient with Cholangiocarcinoma. |
| 01/23/06 |
Scientist’s
passion for pharmaceutical innovation driving cancer
drug trials. |
| 01/13/06 |
Pro-Pharmaceuticals
Announces the Appointment of Anatole Klyosov, Ph.D.,
D.Sc. as Chief Scientist.
Company Continues to Strengthen Intellectual Property
Portfolio—Receives New U.S. Patent for the Delivery
of a Therapeutic Agent to Reduce Toxicity. |
| 12/13/05 |
Pro-Pharmaceuticals
Announces Two International Clinical Sites in Colorectal
Cancer Trial of DAVANAT®/5-FU. |
| 12/09/05 |
Pro-Pharmaceuticals
Issues Corporate Update.
Outlines Achievements and Key Clinical Milestones.
|
| 11/11/05 |
Pro-Pharmaceuticals
to Present at Annual Glycobiology Conference.
Targeting Tumor Lectins, DAVANAT® Shows Promising
Results in Phase I Trial with 5-FU Refractory Patients.
|
| 11/10/05 |
Pro-Pharmaceuticals
Reports Third Quarter Results |
| 11/07/05 |
Pro-Pharmaceuticals
Receives Clearance from EMEA to Initiate International
Phase III Colorectal Cancer Clinical Trial. |
| 11/02/05 |
Pro-Pharmaceuticals
to Present at Techvest Healthcare Conference. |
| 10/25/05 |
Pro-Pharmaceuticals
to Present at Mass Opps
Biotech Investor Conference. |
| 10/14/05 |
Pro-Pharmaceuticals
Reports Enrollment Progress in Phase II Colorectal
Cancer Trial with DAVANAT®/5-FU. |
| 10/06/05 |
Pro-Pharmaceuticals
Announces Final Phase I Results.
Pharmacokinetics Analysis Indicates 5-FU, in Combination
with DAVANAT®, Remains Significantly Longer in
the Bloodstream of Cancer Patients, Potentially Increasing
5-FU’s Efficacy while Lowering Toxicity.
|
| 09/20/05 |
Pro-Pharmaceuticals
to Present New DAVANAT® Data at the International
Society of Oncodevelopmental Biology and Medicine
Conference.
|
| 09/13/05 |
Pro-Pharmaceuticals
Files Phase ll Protocol for DAVANAT®/5-FU in First
Line Cholangiocarcinoma Study.
“Compassionate Use” Patient Continues
to Respond Well after 10 Months of Treatment with
DAVANAT®/5-FU. |
| 08/25/05 |
Pro-Pharmaceuticals
Announces Dosing of Patient with DAVANAT®/5-FU
in Phase II Colorectal Cancer Trial at Ochsner Cancer
Institute. |
| 08/05/05 |
Pro-Pharmaceuticals
Reports Second Quarter Results. |
| 07/28/05 |
Pro-Pharmaceuticals
Announces Termination of SEC Investigation. |
| 07/21/05 |
Vista
Partners Initiates Research Coverage of Pro-Pharmaceuticals.
|
| 07/07/05 |
Pro-Pharmaceuticals
Receives New U.S. Patent for the Delivery of a Chemotherapeutic
Agent to Reduce Toxicity.
New Patent Strengthens the Company’s Intellectual
Property Portfolio. |
| 06/27/05 |
PRO-PHARMACEUTICALS
ADDED TO THE NEW RUSSELL MICROCAP INDEX. |
| 05/19/05 |
PRO-PHARMACEUTICALS
ANNOUNCES DOSING OF CANCER PATIENT with DAVANAT®/5-FU
in a PHASE II CLINICAL TRIAL at HEMATOLOGY-ONCOLOGY
ASSOCIATES of TREASURE COAST |
| 05/17/05 |
PRO-PHARMACEUTICALS’
PHASE II COLORECTAL CANCER TRIAL OF
DAVANAT®/5-FU POSTED TO CLINICAL TRIALS.GOV WEBSITE
Metastatic Colorectal Cancer Trial is Recruiting Patients
for Third- or Fourth-Line Therapy |
| 05/16/05 |
PRO-PHARMACEUTICALS’
PHASE I DATA SHOW DAVANAT®/5-FU WELL-TOLERATED IN
CANCER PATIENTS WITH ADVANCED SOLID TUMORS
Disease Stabilized in 54% of Patients with Measurable
Disease; 60% Stabilized at Highest Dose Level; 71% Received
Additional Cycles |
| 05/13/05 |
Pro-Pharmaceuticals
Reports First Quarter Results |
| 05/12/05 |
PRO-PHARMACEUTICALS
RECEIVES “COMPASSIONATE USE” IND FOR USE
OF DAVANAT®/5-FU WITH A PATIENT WHO HAS CHOLANGIOCARCINOMA
WITH LIVER METASTASES |
| 05/09/05 |
PRO-PHARMACEUTICALS
ANNOUNCES DOSING OF CANCER PATIENT with DAVANAT®/5-FU
in a PHASE II CLINICAL TRIAL at MEDICAL ONCOLOGY &
HEMATOLOGY, P.C. |
| 05/02/05 |
Pro-Pharmaceuticals
to Present at Techvest Global Healthcare Conference |
| 04/27/05 |
Research
Analyst Report on Pro-Pharmaceutials |
| 04/08/05 |
Pro-Pharmaceuticals
Reports Fourth Quarter and Full Year 2004 Results
Annual Shareholders Meeting Scheduled for May 25th |
| 03/22/05 |
Pro-Pharmaceuticals’
Lead Compound DAVANAT® Enhances Anti-Tumor Activity
of Avastin™/5-FU in Pre-Clinical Studies
Data Presented at Glycomics & Carbohydrates Conference
|
| 03/03/05 |
PRO-PHARMACEUTICALS’
FINAL PHASE l ABSTRACT ACCEPTED FOR PUBLICATION IN ASCO
ANNUAL MEETING PROCEEDINGS |
| 02/24/05 |
PRO-PHARMACEUTICALS
ENGAGES WORLDCARE CLINICAL TO ENHANCE AND ACCELERATE
THE PHASE II TRIAL |
| 02/14/05 |
PRO-PHARMACEUTICALS
POSTS ASCO DATA TO ITS WEBSITE
DAVANAT®/5-FU Well Tolerated; Dose Limiting Toxicity
Not Reached; Disease Stabilized in 45% of Patients |
| 02/11/05 |
PRO-PHARMACEUTICALS
NAMES CARL LUEDERS CHIEF FINANCIAL OFFICER |
| 01/27/05 |
PRO-PHARMACEUTICALS’
ASCO DATA SHOW DAVANAT®/5-FU WELL-TOLERATED IN PATIENTS
WITH ADVANCED CANCER
Disease Stabilized in 45% of Patients who Completed
Study through November |
| 01/17/05 |
PRO-PHARMACEUTICALS
COMPLETES ENROLLMENT IN PHASE I TRIAL OF DAVANAT®/5-FU
IN REFRACTORY CANCER PATIENTS |
| 12/14/04 |
PRO-PHARMACEUTICALS’
DAVANAT®/5-FU PHASE l TRIAL DATA TO BE PRESENTED
AT ASCO GASTROINTESTINAL CANCERS SYMPOSIUM |
| 11/30/04 |
Pro-Pharmaceuticals
Responds to The Boston Globe Article |
| 11/22/04 |
Pro-Pharmaceuticals
Reports Third Quarter Results |
| 11/18/04 |
Pro-Pharmaceuticals
'Sets the Record Straight' Regarding Misleading Statements
Made by GlycoGenesys in News Releases |
| 11/12/04 |
Dr.
David Platt Gratified with Arbitrator's Decision: Continues
to Control Prosecution of Modified Pectin Patent Applications |
| 11/08/04 |
PRO-PHARMACEUTICALS
TO PRESENT CORPORATE UPDATE AT BIO-EUROPE 2004 INTERNATIONAL
PARTNERING CONFERENCE |
| 11/03/04 |
PRO-PHARMACEUTICALS
TO PRESENT AT MASS OPPORTUNITIES BIOTECHNOLOGY CONFERENCE |
| 10/21/04 |
PRO-PHARMACEUTICALS
TO PRESENT
AT TECHVEST ANNUAL HEALTHCARE CONFERENCE |
| 10/13/04 |
PRO-PHARMACEUTICALS
TO PRESENT
AT BIO EMERGING COMPANY INVESTOR FORUM |
| 10/04/04 |
PRO-PHARMACEUTICALS
PROVIDES PHASE I TRIAL UPDATE OF DAVANAT® IN REFRACTORY
CANCER PATIENTS |
| 09/30/04 |
PRO-PHARMACEUTICALS
APPOINTS MEDICAL ADVISORY BOARD MEMBERS |
| 09/28/04 |
PRO-PHARMACEUTICALS
RETAINS HANIFY & KING’S LIFE SCIENCES GROUP
TO PURSUE COLLABORATIONS |
| 08/19/04 |
Pro-Pharmaceuticals'
CEO David Platt Granted Patents for Modified Pectin
Material in European Union, Canada, Australia &
New Zealand |
| 08/12/04 |
Pro-Pharmaceuticals
Raises $6 Million |
| 06/23/04 |
PRO-PHARMACEUTICALS
REPORTS PHASE I FOR DAVANAT®-1 IN REFRACTORY CANCER
PATIENTS IS NOW IN ITS SIXTH AND FINAL COHORT |
| 04/07/04 |
Pro-Pharmaceuticals
Raises $4.5 Million |
| 03/24/04 |
Pro-Pharmaceuticals
to Present at Company-Sponsored Carbohydrate Drug Design
Symposium During National Meeting of the American Chemical
Society |
| 03/12/04 |
Pro-Pharmaceuticals
Appoints Jerald K. Rome to Board of Directors |
| 02/25/04 |
Dr.
David Platt and Pro-Pharmaceuticals to Vigorously Contest
Counterclaims Asserted by GlycoGenesys |
| 01/08/04 |
Pro-Pharmaceuticals
to Initiate a Phase II Clinical Trial of its Lead Anti-Tumor
Compound DAVANAT® + 5-FU in Colorectal Cancer |
| 12/17/03 |
Pro-Pharmaceuticals
Names Charles Harney Chief Financial Officer |
| 12/09/03 |
Pro-Pharmaceuticals
Announces the Dosing of Cancer Patients at Florida Oncology
Associates |
| 11/13/03 |
Pro-Pharmaceuticals
Issued Two U.S. Patents for its Core Carbohydrate Drug
Targeting & Delivery Platforms -- CARBOSOME™
& UCLT™ |
| 10/28/03 |
Mass
Opportunities: A Biotechnology Investment Conference,
October 28, 11:30 AM, The Hilton Logan Airport, Boston |
| 10/15/03 |
Pro-Pharmaceuticals
To Present: `Advancing Drugs Through Glycoscience' at
Techvest Healthcare & MassOpps Investment Conferences |
| 10/3/03 |
Pro-Pharmaceuticals
Announces $4.6 Million Private Placement Financing |
| 9/22/03 |
Pro-Pharmaceuticals
rang the opening bell on the American Stock Exchange |
| 9/16/03 |
Animal
Studies Demonstrate the Importance Pro-Pharmaceuticals’
DAVANAT® Played in Significantly Increasing the
Anti-Cancer Efficacy of 5-Fluorouracil |
| 9/15/03 |
Pro-Pharmaceuticals
To Present: Advancing Drugs Through Glycoscience™
at UBS “Global Life Sciences” & Burrill
“Life Sciences Partnering” Conferences |
| 9/10/03 |
American
Stock Exchange Lists Common Stock of Pro-Pharmaceuticals,
Inc. |
| 9/10/03 |
Pro-Pharmaceuticals’
CEO Chairs “Cancer Drugs 2003” Conference |
| 9/10/03 |
Pro-Pharmaceuticals’
Common Stock Begins Trading Today on AMEX® Under
the Symbol “PRW” |
| 9/9/03 |
Pro-Pharmaceuticals’
Common Stock to be Traded on AMEX® Under the Symbol
“PRW” |
| 7/21/03 |
Pro-Pharmaceuticals
Appoints Noted Carbohydrate Chemist Zbigniew J. Witczak,
Ph.D. to Its Scientific Advisory Board |
| 7/15/03 |
Pro-Pharmaceuticals
To Host Corporate Presentations in Denver, Austin &
Chicago |
| 7/2/03 |
Pro-Pharmaceuticals
Announces Publication of Study in Peer-Reviewed Journal
Carbohydrate Research |
| 6/24/03 |
Cancer
Patients Injected With Pro-Pharmaceuticals’ DAVANAT®
in Phase I Clinical Trial at the Norris Cotton Cancer
Center
at Dartmouth-Hitchcock Medical |
| 6/20/03 |
Pro-Pharmaceuticals
To Host Corporate Presentations |
| 5/29/03 |
Pro-Pharmaceuticals
Names Squeglia VP Investor Relations |
| 5/14/03 |
Cancer
Patients Injected With Pro-Pharmaceuticals’ DAVANAT®
in Phase I Clinical Trial at the Ochsner Cancer Institute |
| 4/28/03 |
Pro-Pharmaceuticals
Receives Patent Allowance for Its Carbohydrate Linker
Technology for Anti-Cancer Agents |
| 4/14/03 |
Pro-Pharmaceuticals
Appoints Steven Prelack to Board of Directors |
| 4/3/03 |
Pro-Pharmaceuticals
Reports Year End Results |
| 3/20/03 |
Pro-Pharmaceuticals
Appoints David Christopher as CFO |
| 2/14/03 |
Cancer
Patients Injected With Pro-Pharmaceuticals' DAVANAT®
in Phase I Clinical Trial At Howell, New Jersey Oncology
Clinics |
| 2/6/03 |
Pro-Pharmaceuticals
Initiates Multi-Center Clinical Trials Of DAVANAT®-1
For All Solid Tumors |
| 1/15/03 |
Pro-Pharmaceuticals
Completes Private Placement |
| 1/6/03 |
Pro-Pharmaceuticals
Expands Clinical Cancer Trial to Include Additional
Solid Tumors |
| 12/30/02 |
Pro-Pharmaceuticals
Engages Medidata for Real-Time Electronic Data Collection
in its Clinical Cancer Trial |
| 12/19/02 |
Pro-Pharmaceuticals
Retains PRA International for Clinical Trial In Cancer
Patients |
| 12/10/02 |
Pro-Pharmaceuticals
Presents Overview of Carbohydrate Technology To Enhance
Existing Cancer Drugs |
| 11/15/02 |
Pro-Pharmaceuticals
Reports Third Quarter Results |
| 10/22/02 |
Pro-Pharmaceuticals
Names Medical Director for Upcoming Clinical Study.
Marilyn Pike engaged as clinical development consultant
to oversee firm's Phase I drug trial |
| 10/7/02 |
Pro-Pharmaceuticals
Appoints Mildred Christian to Board of Directors.
Expert on experimental design and government compliance
to serve multiple roles with firm |
| 9/25/02 |
Pro-Pharmaceuticals
Featured in ‘Genetic Engineering News’ Overview
of
Innovative Cancer Therapy Research |
| 9/12/02 |
Pro-Pharmaceuticals Names University of Michigan Medical
School Professor to Scientific Advisory Board. Expert
on specialized protein-carbohydrate chemistry to consult
on upcoming clinical trials. |
| 9/5/02 |
Pro-Pharmaceuticals
Commences Trading on NASD OTC Bulletin Board. Trading
Follows FDA Approval of Human Trials With Cancer Drug
Enhancement Formulation. |
| 8/26/02 |
Pro-Pharmaceuticals
Reports Second Quarter Results |
| 7/29/02 |
Pro-Pharmaceuticals
Receives FDA Approval for Phase I Clinical Trial |
| 7/11/02 |
Pro-Pharmaceuticals
Announces Public Reporting of Financial Results |
